期刊文献+

泰索帝联合阿霉素治疗乳腺癌对心电图的影响 被引量:2

Clinical observation of electrocardiographic changes in response to taxotere combined with adriamycin treatment for breast cancer
下载PDF
导出
摘要 目的探讨化疗药物泰索帝(taxotere)联合阿霉素一线治疗局部晚期或转移性乳腺癌对心电图的影响,并分析其临床意义。方法被确诊为局部晚期或转移性乳腺癌的250例患者,经静脉滴注泰索帝75 mg/m2和阿霉素5 mg/m2,每3周1次,每个疗程开始前和结束后各观测心电图1次,共动态观察10个疗程。结果10个疗程结束后,250例患者中心率加快8 例(3.2%),肢体导联QRS波低电压12 例(4.8%),Q-T时间延长28 例(18 %),ST段压低18例(7.2%),T波低平29例(11.6%),T波倒置12例(4.8%),未发生变化143例(57.2%)。结论化疗药物泰索帝和阿霉素对心脏有毒性,能够引起心包积液和心肌不同程度损伤,造成慢性心肌缺血缺氧,从而引起心电图QRS波群及ST-T的异常改变。 Objective To study the effects of taxotere and adriamycin based chemotherapy on the electrocardiogram (ECG) of patients with locally advanced or metastatic breast cancer. Methods Chemotherapy combining taxotere (75 mg/m2) and adriamycin (5 mg/m2) once every 3 weeks was performed in 250 patients with locally advanced or metastatic breast cancer. Electrocardiograph was recorded before and after each treatment course for a total of 10 courses. Results After the completion of the 10 treatment courses, 8 (3.2%) patients had accelerated heart rate, 12 presented low voltage of QRS complex in the limb leads, and Q-T interval extension, ST segment depression, T-wave flattening, T-wave inversion occurred in 28, 18, 29, and 12 patients, respectively. The rest patients had no ECG changes. Conclusions Taxotere and adriamycin as antitumor chemotherapeutic drugs may cause toxicity in the heart, and result in pericardial effusion, myocardial injury, chronic myocardial ischemia or hypoxia that may lead to abnormal changes in QRS complex and ST-T segment in ECG.
出处 《第一军医大学学报》 CSCD 北大核心 2004年第5期582-583,共2页 Journal of First Military Medical University
关键词 泰索帝 阿霉素 治疗 乳腺癌 心电图 taxotere adriamycin breast cancer/treatment myocardial injury electrocardiogram ST-T change
  • 相关文献

参考文献6

二级参考文献34

  • 1徐仁宝 谭金兴.病理性应激时大鼠肝胞液糖皮质激素受体的变化[J].生理学报,1982,34(4):460-5.
  • 2乐颖影 李晓文.大鼠肾胞浆糖皮质激素受体的测定[J].生理通讯,1998,18(1):30-3.
  • 3Potier P. The synthesis of navelbine, prototype of a new series of vinblastine derivatives[J]. Semin Oncol, 1989, 16 (Suppl 4): 2-4.
  • 4Fellous A, Meininger V, Binet S, et al. Action of navolbine(NVB)on microtubules. Role of Tan and MAP2 proteins[A]. In: Pierre F.Navelbine: update and new trends[M]. Isted Franc: John Libbey Eurotext Led, 1991.9.
  • 5Cros S, Takooudju M, Shaepelynck L. Comparative in vitro and in vivo study of navelbine ditartate (nor 54 anhydrovinblasline) with the two antitumor compounds: vinblastine and vinecristine. Proceeding of the 14th International Congress of Chemotherapy. Tokyo Japan. June 23-28,1985[J]. Recent Adv Chemother, 1985, 1: 477-8.
  • 6Chevalier TL, Briggand D, Douillard JK, et sl. Randomized study of vinorelbine and cisplatin versus vindcsine and cisplatin versus vinorelbine alone in advanced non- small cell lung cancer:results of a European multicenter trial including 612 patients[J]. Clin Oncol,1994, 12(2): 360-4.
  • 7Bonadonna G. Vinorelbine:an active noncross-resistnt drug in advanced breast cancer result from a phase Ⅱ study[J] Breast Cancer Res Treat, 1996, 39(3): 285-91.
  • 8Ray-coquard I, Biron P, Baehelot T, et al. Vinovelbine and cisplatin for treatment of metastatic breast cancinoma after failure of anthracydine-and/or paclitaxel- containing regimens[J]. Cancer, 1998, 82(1): 134-40.
  • 9Kurebayashi J. Biological and clinical significance of HER2 overexpression in breast cancer[J]. Breast Cancer, 2001, 8(1): 45-51.
  • 10Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis[J]. J Mamm Gland Biol Neopl, 2001, 6(4):393-406.

共引文献41

同被引文献6

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部